Navigation Links
Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit

Richard Wenzel and his colleagues from United Kingdom have found a new antibiotic tigecycline which belongs to the family of new generation of Tetracycline known as Glycycline. //

Due to indiscriminate use of antibiotics there is an increased incidence of antibiotic resistance shown by many organisms. Staphylococcus aureus is a gram positive bacteria, which is a major cause of concern as it causes most of the nosocomial infections in hospital. Staphylococcus aureus as shown an increased resistance to many drugs including the different analogues of Tetracycline and Vancomycin.

Drug – Tetracycline: Tetracyclines were first discovered 50 years ago and were found to have broad spectrum antibacterial activity against both gram positive and gram negative bacteria. Following their initial widespread use, a high incidence of tetracycline resistance among many bacteria has led to tetracyclines being relegated to second- or third-line therapy. As increases resistance to tetracycline have developed there are lot of approaches to restore the potential of tetracyclines as broad-spectrum antibiotics, systematic searches for tetracycline analogues with activity against both tetracycline-susceptible and tetracycline-resistant organisms were performed in the early 1990s which has led to the identification of the glycylcyclines, including tigecycline.

Properties of Tigecycline: Tigecycline was discovered by introducing substituents at position 9 of minocycline resulted in compounds that not only had activity typical of earlier tetracyclines, but also displayed activity against bacteria containing resistant genes.

Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Tigecycline blocks entry of amino-acyl tRNA molecules into the A site of the ribosome, preventing incorporation of amino-acid residues into elongating peptide chains. Tetracycline drug resistance in bacteria occurred due to mechanisms of ribosomal protection and active drug efflux. But, the new generation tetracycline - Tigecycline is not affected by either of these mechanisms.

Clinical studies and FDA approval: Two clinical studies proving the active effect of Tigecycline as lead to FDA approval of Tigecycline for treatment of bacterial infections.

Study I: Tigecycline was tested on patients with complicated skin and skin-structure infections.

The study was performed in 800 adult patients. Tigecycline was given in a concentration of 100 mg intravenous initial dose followed by 50 mg every 12 hours which was compared with vancomycin 1 g intravenously every 12 hours/aztreonam 2 g intravenously every 12 hours for 5–14 days.

Study II: Tigecycline was tested in patients with complicated intra-abdominal infections

The study was performed in more than 1,000 adult patients. Tigecycline was given at a dosage of 100 mg intravenous initial dose followed by 50 mg every 12 hours which was compared with imipenem/cilastatin 500 mg intravenously every 6 hours for 5–14 days.

Tigecycline has great promise as a new therapeutic agent against important pathogens and is highly active against both nosocomial and Methicillin Resistant S. aureus strains (MRSA), vancomycin resistant E. faecium and penicillin resistant strains of S. pneumoniae. Though, Tigecycline's structure is similar to that of the tetracyclines but additional structural elements increase its potency and impede the mechanisms of bacterial resistance associated with the tetracyclines.

Source: Nature Reviews Drug Discovery
'"/>




Related medicine news :

1. Hearing Problems Of Middle Age Are Affecting The Younger Generation
2. Newer Generation Sleeping Pills Lack Superior Performance
3. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
4. Moles Among The Older Generation May Be Dangerous
5. Leptin, The Next Generation Antidepressant?
6. Generation Scotland To Examine Relation Between Lifestyle, Genetics and Health
7. Baby Gloom: ‘Baby Gap’ Generation Signals Babies’ Days Ot!
8. Researchers Aim To Develop Next Generation Of Surgical Robots
9. New Generation Teenagers Addiction to Prescription Drugs
10. New Generation - Medicinal Products
11. Take Third Generation Oral Contraceptives Off the Shelves-consumer Group Insists
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology: